Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Gastrointestinal Stromal Tumors 10Sarcoma 1Renal Insufficiency 1Penile Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Mastocytosis, Systemic 1Mast Cell Activation Disorders 1Leukemia, Mast-Cell 1Glioma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 13Etoposide 11Paclitaxel 8Cyclophosphamide 7Carboplatin 7Ifosfamide 6etoposide phosphate 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5pembrolizumab 4fludarabine 4Sirolimus 4Bleomycin 4fludarabine phosphate 3Sunitinib 3Oxaliplatin 3Mesna 3Melphalan 3Filgrastim 3Drug Therapy 3Brentuximab Vedotin 3Bevacizumab 3Automobiles 3130-nm albumin-bound paclitaxel 3tremelimumab 2sodium thiosulfate 2ribociclib 2pralsetinib 2pegfilgrastim 2durvalumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms, Germ Cell and Embryonal × ripretinib × Clear all
NCT02571036 2023-12-13

A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies

Deciphera Pharmaceuticals, LLC

Phase 1 Completed
282 enrolled
CNSDermatologicGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmSarcomaThoracic

Mast Cell Activation Disorders, Carcinoma, Non-Small-Cell Lung, Glioma, Leukemia, Mast-Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Penile Neoplasms, Sarcoma, Mastocytosis, Systemic, Gastrointestinal Stromal Tumors, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡